Procoralan: new option for chronic heart failure

Procoralan (ivabradine) can now be prescribed for the treatment of chronic heart failure as an addition to standard therapy.

Procoralan is also licensed for the treatment of chronic stable angina
Procoralan is also licensed for the treatment of chronic stable angina
The double-blind SHIFT study compared ivabradine, the only licensed sinus node If inhibitor, with placebo in patients with stable chronic heart failure (NHYA class II to IV). Patients were randomised to receive ivabradine 7.5mg twice daily (n=3268) or placebo (n=3290), and were permitted to continue stable background therapy (including β-blockers) if tolerated. Investigators used a composite of cardiovascular death or hospital admission for worsening heart failure as the primary endpoint, and all analyses were based on the intention to treat population.

At the end of the follow-up period (median 22.9 months), fewer patients met the primary endpoint in the ivabradine group (793 events) than in the control group (937 events), resulting in a hazard ratio of 0.82 (95% CI 0.75-0.90; p<0.0001).

View Procoralan drug record

Further information: Servier Laboratories Ltd


Read these next

Monitor patients taking ivabradine for bradycardia, EMA recommends

Monitor patients taking ivabradine for bradycardia, EMA recommends

In light of preliminary data from the SIGNIFY study,...

Ivabradine approved by NICE for heart failure

Ivabradine approved by NICE for heart failure

The National Institute for Health and Clinical Excellence...

Use of Inspra in heart failure extended

Use of Inspra in heart failure extended

Inspra (eplerenone) has been approved for use with...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases